Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 7,220 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $87.63, for a total transaction of $632,688.60. Following the transaction, the insider now owns 149,096 shares of the company’s stock, valued at approximately $13,065,282.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Haig P. Bozigian also recently made the following trade(s):
- On Monday, May 13th, Haig P. Bozigian sold 34,547 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $75.51, for a total transaction of $2,608,643.97.
Shares of NBIX stock traded down $0.25 during trading hours on Friday, hitting $85.70. 413,922 shares of the company were exchanged, compared to its average volume of 868,841. The stock has a market cap of $7.80 billion, a price-to-earnings ratio of 389.55 and a beta of 1.34. Neurocrine Biosciences, Inc. has a 1 year low of $64.72 and a 1 year high of $126.98. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.61 and a current ratio of 8.79. The business’s fifty day moving average price is $83.48.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, April 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative net margin of 7.56% and a negative return on equity of 9.14%. The business had revenue of $138.40 million during the quarter, compared to analysts’ expectations of $136.77 million. During the same quarter in the previous year, the business posted ($0.47) EPS. The company’s quarterly revenue was up 94.7% on a year-over-year basis. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post -0.04 earnings per share for the current year.
A number of equities analysts have commented on the stock. Barclays set a GBX 6,800 ($88.85) price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Friday, March 29th. Evercore ISI initiated coverage on shares of Homology Medicines in a research note on Thursday, April 11th. They set an “outperform” rating and a $29.00 price target on the stock. Guggenheim initiated coverage on shares of resTORbio in a research note on Tuesday, June 4th. They set a “buy” rating and a $28.00 price target on the stock. ValuEngine raised shares of ZTE CORP/ADR from a “hold” rating to a “buy” rating in a research note on Monday, April 15th. Finally, Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 20th. They set a “neutral” rating and a $336.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $102.16.
A number of hedge funds and other institutional investors have recently bought and sold shares of NBIX. Acadian Asset Management LLC purchased a new position in Neurocrine Biosciences in the fourth quarter valued at approximately $32,000. Evolution Wealth Advisors LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $40,000. Quadrant Capital Group LLC raised its stake in shares of Neurocrine Biosciences by 9,242.9% during the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after purchasing an additional 647 shares during the period. Arbor Wealth Management LLC purchased a new stake in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $92,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Neurocrine Biosciences by 75.2% during the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,120 shares of the company’s stock valued at $151,000 after purchasing an additional 910 shares during the period. Hedge funds and other institutional investors own 95.86% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Further Reading: Correction
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.